In the space of two weeks, ProMetic’s potential blockbuster lead small molecule candidate PBI-4050 has delivered positive data from the clinic, from two open label Phase II trials. The latest data announced this week is from a study in the Metabolic Syndrome and Type 2 Diabetes study and confirms the efficacy reported at earlier points in the study with the significant reductions in HbA1c (glycated haemoglobin) originally observed at 12 weeks being maintained at 24 weeks. Significant re
21 Oct 2016
Successful Phase 2 Metabolic Syndrome and Type II diabetes trial also bodes well for larger Chronic Kidney Disease study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful Phase 2 Metabolic Syndrome and Type II diabetes trial also bodes well for larger Chronic Kidney Disease study
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
21 Oct 2016 -
Author:
Derren Nathan -
Pages:
6
In the space of two weeks, ProMetic’s potential blockbuster lead small molecule candidate PBI-4050 has delivered positive data from the clinic, from two open label Phase II trials. The latest data announced this week is from a study in the Metabolic Syndrome and Type 2 Diabetes study and confirms the efficacy reported at earlier points in the study with the significant reductions in HbA1c (glycated haemoglobin) originally observed at 12 weeks being maintained at 24 weeks. Significant re